Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 7, 2004 Charly Travers	Unraveling Biotech Potential The author shows investors how to forecast the potential of drug sales.
Wall Street & Technology February 27, 2005 Maria Santos	Making Monte Carlo Work The National Association of Securities Dealers (NASD) has lifted the ban on Monte Carlo simulation tools.
Investment Advisor September 2006 Mike Patton	Risk Manager A view from the trenches on the benefits and drawbacks of the financial planning profession's Monte Carlo simulation. When the software is used properly, the client wins, the practitioner wins, and the financial services industry wins.
Financial Advisor September 2009 Joel P. Bruckenstein	What Are The Odds? A look at whether Monte Carlo simulations help or hinder the planning process.
Registered Rep. January 1, 2009 Brent E. Bentrim	Letters Two articles espousing the merits of Monte Carlo Simulations (MCS) were alarming.
Wall Street & Technology January 9, 2006	IPlan Adds Monte Carlo Sims Ibbotson Associates has added Monte Carlo simulations to version 2.0 of iPlan, its Web-based investment planning software.
Financial Advisor May 2010 Joel P. Bruckenstein	Getting Risk Right More retirement planning programs now consider "fat tails."
Investment Advisor October 2007 Mike Patton	Simulation Wizardry The myriad of off-the-shelf financial planning programs contain many limitations. Through the use of Crystal Ball software, the frontier has been expanded significantly.
Financial Planning August 1, 2005 John Nersesian	The Full Monte By presenting clients with a range of potential results before they experience them and showing them the impact of their investment choices, planners can manage clients' expectations much better than with standard linear forecasting.
The Motley Fool August 2, 2004 Charly Travers	What's a Drug Worth? The value of small biotech companies is in their investigational drug programs.
CIO January 1, 2003 Michael Schrage	When Good People Make Bad Decisions New economic research affirms what most executives suspect: Even when given good data, people make bad decisions. We misunderstand, misinterpret and mismanage important problems. There are technologies emerging now to help us fix those bugs.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
Financial Advisor August 2009 Bruce W. Fraser	Last Hand For Monte Carlo? Monte Carlo simulation, a popular retirement planning tool, is under scrutiny.
Chemistry World February 8, 2011 Elinor Richards	The true cost of getting energy from the sun Scientists from Argonne National Laboratory in Illinois have used a simulation that gives distributions of values for variable parameters such as weather, solar panel performance, operating costs and inflation to more accurately reflect the overall cost.
The Motley Fool May 28, 2004 Charly Travers	Don't Be a Biotech Gambler Stand on solid ground by learning to assess the value of future drug programs. Investing in biotechs -- rather than simply speculating in the sector -- requires a solid assessment of how much a company's drug programs could be worth.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
CIO July 1, 2003 Scott Berinato	Playing with Fire IT is late to embrace risk analysis, but without it, project portfolio management is nothing more than a fad.
Science News September 27, 2003 Ivars Peterson	The Bias of Random-Number Generators Researchers in Germany have provided some mathematical insight into why many random-number generators give wrong results in so-called cluster Monte Carlo simulations and related computational experiments.
IEEE Spectrum November 2008 Samuel K. Moore	PlayStation 3 Processor Speeds Financial-Risk Calculation Georgia Tech's parallel processing code for PlayStation 3's Cell processor makes mountains of random numbers to improve Value-at-Risk and other important algorithms
Bio-IT World Dec 2006/Jan 2007 Mark D. Uehling	Vertex Views Trial Supplies For a recent clinical trail, the head of clinical development systems at Vertex Pharmaceuticals found a new software offering from Tourtellotte Solutions.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
CFO March 1, 2012 Vincent Ryan	Slippery Slope Assessing the volatility of oil prices, and developing a strategy to cope with them, stymie many finance departments.
Financial Advisor September 2010 Andrew Gluck	Broken Plans Financial advisors urgently need improved tools for coping with the economic mess we're in. What's to be done?
Financial Advisor May 2008 Joel Bruckenstein	Retirement Good Fortune Silver Financial Planner from MoneyTree Software is one of the top choices for advisors looking for a dedicated retirement planning tool.
Chemistry World March 20, 2014 Ricardo Grau-Crespo	Introduction to computational materials science This book by Richard LeSar attempts to summarize the basics and the current state of the whole field within a single, and not very lengthy, volume. It does so very successfully.
The Motley Fool February 28, 2011 Brian Orelli	Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out?
Wall Street & Technology May 25, 2005 Maria Santos	Innovative Technologies & Services Monte Carlo Hits Top Speed... Customized Reporting Made Easy... Teaming Up for Data Auditing...
Financial Planning January 1, 2006 Glenn G. Kautt	Factors 1-2-3 Fama and French's famous model explains variances in stock prices -- but another three-factor model explains major changes in the value of your firm.
HBS Working Knowledge August 18, 2003 Lovallo & Kahneman	Optimism: Don't Let it Run Away with You Many M&A decisions may be the result of hubris. Here's a technique to help executives avoid the bad kind of optimism.
The Motley Fool November 2, 2004 Charly Travers	Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer.
Bank Systems & Technology February 11, 2004 Ivan Schneider	Rock-a-bye-Baby Boom You don't have to be young to seek sound advice, especially in financial planning. The great demographic surge is almost upon us. And members of the baby-boom generation, from the wealthy to the fabulously wealthy to the merely well-off, all need good financial advice.
Investment Advisor June 2009 Mike Patton	Temperament & Tools To do the job right, the fiduciary financial planner needs the right temperament, and the right tools. Here's how one advisor does it.
Registered Rep. August 28, 2002 Rick Weinberg	NASD Looks To Approve Broker, Brokerage Firm Use of Investment Analysis The NASD is looking to approve a proposal that would allow brokers and brokerage firms to provide clients with interactive investment analysis tools.
Science News October 16, 2004	A Catalog of Random Bits A computer scientist and collaborators have identified a variety of flaws in computer-based random number generators, invented more robust versions of existing generators, and developed a suite of rigorous tests to check for randomness... Puzzle of the Week...
The Motley Fool August 26, 2010 Travers & Jayson	Will Onyx Pharmaceuticals Burn You? Is Onyx Pharmaceuticals on strong financial footing?
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool March 4, 2004 Brian Gorman	Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates.
Financial Advisor September 2006 Cohen & Overgard	Asset Allocation And Investor Goals What investors and financial advisors should know about portfolio construction from the first decade of hedge funds.
Registered Rep. November 1, 2002 Ross Tucker	NASD Wants to OK Use of Predictive Tools by Brokers NASD member firms want to revise the association's Rule 2210 to make sure that they, too, can use these tools, including Monte Carlo simulations, to help clients make investment decisions.
The Motley Fool October 31, 2006 Emil Lee	How to Calculate the Kelly Formula Although any formula is only as good as the estimates and data plugged into it, this formula forces investors to think in terms of payoffs and probabilities when investing in a company.
Chemistry World July 6, 2007 Michael Gross	Predicting How Proteins Fold Researchers in Italy and the UK have now developed a computational approach that can simulate the folding of membrane proteins in atomic detail.
The Motley Fool October 9, 2006 Brian Lawler	The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field.
The Motley Fool July 12, 2004 Brian Gorman	India Woos U.S. Biotech Companies Business abroad would bode well for investors and consumers.
The Motley Fool August 17, 2010 Travers & Jayson	Is Alexion Pharmaceuticals Burning Out? The first step toward finding a promising biotech company is not to figure out whether the science is any good, but to make sure that the company is financially healthy.
The Motley Fool August 17, 2010 Travers & Jayson	How Long Can Amylin Pharmaceuticals Last? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big.
Investment Advisor July 2006 Melanie Waddell	Retirement Planning: Keying Into Income Needs Two of the top providers of financial planning software -- Morningstar and EISI -- are heeding advisors' calls for help in crafting retirement distribution strategies.
Financial Advisor January 2005	Frontline News America Views The Economy In Shades Of Red And Blue... Regulators OK Monte Carlo Tools... TD Waterhouse Backs FPA Stand Against SEC Rule... PowerBroker To Offer Free Edition For Planning Students... etc.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool November 30, 2004 Charly Travers	Picking Biotech's Winners Doing well as a biotech investor comes as much from avoiding the losers as picking the winners. A quick screen for making winning investment picks.
The Motley Fool August 18, 2010 Travers & Jayson	Interested in Elan? Start Here! You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big.